Retatrutide 20mg Metabolism

Lyophilised · HPLC 99.8% · COA online

105,00 €
Tax included • Free delivery from 119€
1 vial = 5 to 10 weeks at 2-4 mg per week
+5,25 € cashback with an account: Create my account
1
18 in stockships Wednesday, November 4
Subscription
94,50 €-10 %instead of 105,00 €

-10 % for life on each cyclePause, skip or cancel in 1 clickNo commitment, no hidden fees

No card: each delivery is paid in Bitcoin (extra -5%) or by bank transfer

Your complete kit

The vial alone cannot be used as is. Add what you need to prepare it:

20mg vialIncluded
Eau Bactériostatique
7,90 €

Frequently bought together

GHK-Cu
GHK-Cu 100mg49,00 €
MOTS-c
MOTS-c 10mg32,00 €
Melanotan 2
Klow
Klow 80mg95,00 €

Research Use Only (RUO) · Prohibited for human or veterinary use.

Key facts

Retatrutide is a synthetic peptide supplied lyophilised, intended exclusively for laboratory scientific research. Technical sheet, storage and analyses below.

Protocol and preparation

Reconstitution for this format (20 mg)Standard volumes used in laboratory settings
Water addedConcentrationReading marker
2 ml10 mg/ml10 UI = 1 mg
3 ml6,67 mg/ml40 UI = 2,67 mg

The volume of water does not change the product, only its concentration. Add the water slowly along the vial wall, then swirl without shaking.

  1. Asepsis

    Disinfect surfaces and stoppers (70% alcohol).

  2. Solvent

    Draw the required volume of bacteriostatic water.

  3. Introduction

    Add gently against the vial wall (avoid a direct jet on the powder).

  4. Solubilization

    Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storage Once reconstituted: 2-8°C (refrigerator).

Warning Theoretical tool for chemical handling. Does not constitute medical advice.

I open the dilution calculator
What is normal on arrivalThe observations that worry customers, and are not defects
  • The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
  • The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
  • The vial carries no individual label. That is our standard packaging, not a downgraded vial.
  • After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
  • The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Vial markings
  • 0.25 mg = 2.5 IU (weeks 1 to 4)
  • 0.5 mg = 5 IU (weeks 5 to 8)
  • 1 mg = 10 IU (weeks 9 to 12)
  • 2 mg = 20 IU (weeks 13 to 16)
  • 4 mg = 40 IU (from week 17, if 2 mg is well tolerated)

Role of the 20 mg vialMaintenance, once the 0.25 to 2 mg steps are done on the small formats (5 mg, then 10 or 15 mg).

Titrating on this vialPossible, but 0.25 mg = 2.5 IU requires a very fine graduation. The 5 mg vial (0.25 mg = 5 IU) is simpler for the first weeks.

OrganisationWrite the reconstitution date on the label, keep the vial in the fridge between 2 and 8 °C, away from light.

Research monitoringMetabolic panel every 4 weeks, liver panel every 8 weeks, heart rate every week, site rotation logged, adverse-effect log daily for the first 4 weeks then weekly.

Technical data

Reconstitution
2 ml d'eau → 10 mg/ml. 5 UI = 0,5 mg ; 10 UI = 1 mg ; 20 UI = 2 mg ; 40 UI = 4 mg. Attention : deux fois plus concentré que les flacons de 5 et 10 mg (5 mg/ml), ne pas reprendre leurs repères. Pour démarrer à 0,25 mg, prendre le flacon de 5 ou 10 mg.
Peptide sequence
YXQGTFTSDYSILLDKKAQXAFIEYLLEGGPSSGAPPPS-NH2 (X = Aib ; lysine acylée)
Molecular formula
C221H342N46O68
Molecular weight
4731.34 g/mol
CAS number
2381089-83-2
Physical form
Poudre lyophilisée
Recommended solubility
Eau bactériostatique, NaCl 0,9%
Storage conditions
Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
Use
Research reagent, in vitro only (RUO)

Storage & handling

Lyophilized retatrutide stores up to 24 months between 2 and 8 °C, protected from light, in its original borosilicate vial sealed under inert atmosphere. The peptide is stable in solid form; degradation pathways become operational only after solubilization. Extended stocks can tolerate -20 °C (deep freeze) without documented integrity loss, provided freeze-thaw cycles are avoided as they introduce mechanical stress on tertiary structure.

After reconstitution with bacteriostatic water (0.9% benzyl alcohol), the solution stores for 21-28 days at 2-8 °C, protected from light. The C20 diacid chain is more hydrophobic than semaglutide's (C18) and tirzepatide's, slightly slowing degradation but increasing oligomerization propensity if the solution undergoes agitation or shear. Dominant degradation pathways: methionine oxidation (specifically Met30), asparagine deamidation (Asn25, Asn35) pH-sensitive, aspartate isomerization, and oligomerization/fibrillation via the C20 lipid anchor. After 28 refrigerated days, typically expect 5-10% activity loss, acceptable for most research protocols.

Operational recommendations(1) handle the reconstituted vial with powder-free nitrile gloves to avoid surface contaminants that would catalyze degradation; (2) never vortex or shake, prefer gentle rotation with the vial tilted at 45 degrees until complete dissolution (typically 30-60 seconds); (3) if a precipitate persists after 5 minutes, warm gently to 25 °C (hand, never > 30 °C); (4) post-reconstitution storage must be a constant 2-8 °C, ideally low in the fridge (thermally most stable area), in a peptide-dedicated compartment (no contact with food or other volatile products).

Mechanism of action

Retatrutide is the first triple incretin-mimetic agonist to reach phase II/III clinical development. Its sequence combines three activities: GLP-1R, GIPR, and GCGR (glucagon receptor), a design that unites in a single molecule the three main metabolic levers of energy regulation. Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days. The affinity profile is calibrated for triple balance: full agonist at GIPR, full agonist at GLP-1R, partial agonist at GCGR, preserving glycemia while exploiting glucagon thermogenic benefits.

Frequently asked questions

How long can reconstituted retatrutide be stored, and what signs indicate degradation?
21-28 days at 2-8 °C protected from light. The benzyl alcohol in bacteriostatic water preserves microbial sterility but not chemical integrity. Degradation pathways: Met30 oxidation, Asn25/35 deamidation, oligomerization via C20 diacid chain (more hydrophobic than semaglutide's C18, therefore more prone to protein interactions). Visual signs: persistent cloudiness, precipitate, crystals, yellow or amber color, flocculation on gentle swirl. A uniform haze with no particles in suspension is expected with this molecule: it affects neither its identity nor its purity and is not a reason to discard the vial. What does justify discarding it is particles that stay in suspension, a deposit that will not redissolve, crystals, or a yellow colour. If in doubt about any of those, discard and reconstitute. Expected activity loss 5-10% after 28 days. For long cycles, plan reconstitutions to minimize time since reconstitution.
Can retatrutide be combined with other research peptides (BPC-157, TB-500, CJC-1295, ipamorelin)?
Combinations are explored in advanced research contexts. BPC-157 and TB-500 (healing and tissue repair) are pharmacodynamically orthogonal to retatrutide, no interaction expected. CJC-1295 + ipamorelin (GH/IGF-1 stimulation) can potentiate certain metabolic effects and require enhanced glycemic monitoring, especially given the retatrutide glucagon arm which may add to the gluconeogenic effect of the GH axis. No direct pharmacokinetic interaction expected (retatrutide proteolytic clearance, no CYP450). In exploratory research, documenting each combination and observed effects is essential to exploit data value.
Full guide: Retatrutide — mechanism and studies
Retatrutide (LY3437943): complete guide to the triple agonistThe complete guideRetatrutide (LY3437943): complete guide to the triple agonistRead the guide
Research field

Metabolism

Metabolism: synthetic peptides for laboratory research, HPLC-analysed.

Explore the range